来源:药研网1月29日,CDE官网公示,信达生物一类新药IBI3028的临床试验申请获得批准,用于标准治疗失败的局部晚期、不可切除或转移性实体瘤。据公开资料显示,IBI3028是一款双抗双毒素抗体偶联药物(bispecific dual-payload ADC)。IBI3028基于信达生物自主研发的DuettX 双载荷 ADC 平台构建,创新性地将双特异性抗体与两种作用机制不同的细胞毒性载荷相结合...
Source Link来源:药研网1月29日,CDE官网公示,信达生物一类新药IBI3028的临床试验申请获得批准,用于标准治疗失败的局部晚期、不可切除或转移性实体瘤。据公开资料显示,IBI3028是一款双抗双毒素抗体偶联药物(bispecific dual-payload ADC)。IBI3028基于信达生物自主研发的DuettX 双载荷 ADC 平台构建,创新性地将双特异性抗体与两种作用机制不同的细胞毒性载荷相结合...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.